Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates.

Saved in:
Bibliographic Details
Title: Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates.
Authors: Saunders KO; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA kevin.saunders@dm.duke.edu barton.haynes@duke.edu.; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA., Santra S; Beth Israel Deaconess Medical Center, Harvard University School of Medicine, Boston, Massachusetts, USA., Parks R; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Yates NL; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Sutherland LL; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Scearce RM; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Balachandran H; Beth Israel Deaconess Medical Center, Harvard University School of Medicine, Boston, Massachusetts, USA., Bradley T; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Goodman D; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Eaton A; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA., Stanfield-Oakley SA; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA., Tartaglia J; Department of Research and Development, Sanofi Pasteur, Swiftwater, Pennsylvania, USA., Phogat S; Department of Research and Development, Sanofi Pasteur, Swiftwater, Pennsylvania, USA., Pantaleo G; Division of Immunology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.; Division of Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.; Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland., Esteban M; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Madrid, Spain., Gomez CE; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Madrid, Spain., Perdiguero B; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Madrid, Spain., Jacobs B; Biodesign Institute, School of Life Sciences, Arizona State University, Tempe, Arizona, USA., Kibler K; Biodesign Institute, School of Life Sciences, Arizona State University, Tempe, Arizona, USA., Korber B; Los Alamos National Laboratory and New Mexico Consortium, Los Alamos, New Mexico, USA., Montefiori DC; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA., Ferrari G; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA., Vandergrift N; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Liao HX; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Tomaras GD; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.; Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.; Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA., Haynes BF; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA kevin.saunders@dm.duke.edu barton.haynes@duke.edu.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.; Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA.
Source: Journal of virology [J Virol] 2018 Mar 28; Vol. 92 (8). Date of Electronic Publication: 2018 Mar 28 (Print Publication: 2018).
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society For Microbiology Country of Publication: United States NLM ID: 0113724 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1098-5514 (Electronic) Linking ISSN: 0022538X NLM ISO Abbreviation: J Virol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1098-5514
DOI:10.1128/JVI.02035-17